Investing Profile

Liam Ratcliffe

InvestorVCAngel

Head of Biotechnology at Access Biotechnology

accessbio-tech.comNew York, New York

‌

‌

‌

Your Intro Paths to Liam Ratcliffe

‌

‌

‌

‌

‌

‌

‌

‌

‌

‌

‌

‌

Find Liam Ratcliffe on

cb

Current Investing Position

Access Biotechnology Investor

Investment Range

$100K - $5.0M

Sweet Spot

$1.5M

Investments On Record

20

Liam Ratcliffe is on these Sector & Stage Rankings

Pharmaceuticals (Seed)BioTech (Series B)BioTech (Seed)Pharmaceuticals (Series B)Pharmaceuticals (Series A)BioTech (Series A)New York City Therapeutics (Series A)Therapeutics (Series B)Therapeutics (Seed)

Liam Ratcliffe's Investments On Record (12)

Company	StageDateRound Size	Total Raised
Eliem Therapeutics	Series BMay 2021$60M Series AMar 2021$80M	$260M
Co-investors: Andrew Levin (RA Capital), Ohad Hammer (Pontifax Venture Capital)
Shoopy	SeedFeb 2021$250K	$250K
Passage Bio	Series BSep 2019$110M Series AFeb 2019$120M	$230M
Co-investors: Carl Gordon (OrbiMed), Patrick Heron (Frazier Healthcare Partners)
CuraSen Therapeutics	Series AOct 2018$55M	$55M
Arvinas	Series CApr 2018$55M Series BOct 2015$42M	$140M
Co-investors: Stephen Squinto (OrbiMed), Colleen Cuffaro (Canaan Partners), Tim Shannon (Canaan Partners), Kush Parmar (5am Ventures), Andrew Levin (RA Capital), Daniel Wagner (Connecticut Innovations), Jakob Loven (Nextech Invest), Martin Alexander Gershon (Endeavor Venture Funds)
Aptinyx	Series BDec 2017$70M Series AMay 2016$65M	$140M
Co-investors: Adam Koppel (Bain Capital Life Sciences)
Neuronetics	Series GJun 2017$15M Series FApr 2015$34M Series EMay 2011$30M Series DOct 2009$30M	$170M
Co-investors: Bruce Cleveland (Wildcat Ventures), Leslie Bottorff (GE Ventures), Gil Kliman (InterWest), Kevin Bitterman (Atlas Venture)
Deciphera Pharmaceuticals	Series BSep 2015$75M	$75M

Investors who invest with Liam Ratcliffe

Christine Borowski

Access Biotechnology

Access Biotechnology

Frazier Healthcare Partners